TACTILE SYSTEMS TECHNOLOGY INC (TCMD)
Sector: Health Care
2026 Annual Meeting Analysis
TACTILE SYSTEMS TECHNOLOGY INC · Meeting: May 6, 2026
Directors FOR
9
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Directors
Long-tenured director (since 2015) with extensive medical device CFO and board experience; the company's 3-year price return of +67.0% outpaces the IHI — iShares US Medical Devices ETF return of +4.5% by +62.5pp, which is below the 65pp trigger threshold for strong-positive absolute TSR, so no TSR trigger fires; no overboarding, attendance, or independence concerns identified.
Director since 2022 with strong healthcare CEO background (LifeScan/Johnson & Johnson); TSR trigger does not fire as the +62.5pp gap vs. IHI — iShares US Medical Devices ETF is below the 65pp threshold; no overboarding, attendance, or independence concerns.
CEO and director since 2021 with relevant medical device and health economics experience at Medtronic and Johnson & Johnson; TSR trigger does not fire as the +62.5pp gap vs. IHI — iShares US Medical Devices ETF is below the 65pp threshold; subject to the same TSR screen as all directors per policy, and the screen passes.
Director since 2017 with deep durable medical equipment CEO experience (Inogen); TSR trigger does not fire as the +62.5pp gap vs. IHI — iShares US Medical Devices ETF is below the 65pp threshold; serves on two boards (TCMD and Avation Medical private), no public overboarding concern.
Director since 2025 (less than 24 months ago), making her exempt from the TSR trigger under the new-director exemption; brings relevant medical device CEO experience from Elucent Medical, NeuWave Medical, and GE Healthcare; no other concerns identified.
Director since March 2026 (just recently appointed), fully exempt from the TSR trigger as a new director; brings healthcare marketing and growth expertise from DispatchHealth and Healthgrades; no overboarding or independence concerns.
Director since 2022 with extensive healthcare technology CEO experience (Cerner, Philips); TSR trigger does not fire as the +62.5pp gap vs. IHI — iShares US Medical Devices ETF is below the 65pp threshold; serves on two public boards (Baxter, Veracyte) plus TCMD — three total public boards, which is below the four-board overboarding threshold.
Director since 2023 with strong CFO and financial expertise (NatureWorks, NxThera, Tornier), serving as Audit Committee Chair and designated financial expert; TSR trigger does not fire as the +62.5pp gap vs. IHI — iShares US Medical Devices ETF is below the 65pp threshold; no other concerns.
Director since 2023 with relevant clinical, health technology, and payor experience at Verily and Blue Cross Blue Shield of Louisiana; TSR trigger does not fire as the +62.5pp gap vs. IHI — iShares US Medical Devices ETF is below the 65pp threshold; no overboarding or attendance concerns.
All nine director nominees pass the policy screens. The company's 3-year stock return of +67.0% outperforms the IHI — iShares US Medical Devices ETF (+4.5%) by +62.5 percentage points, which falls just short of the 65pp trigger threshold applicable when absolute 3-year TSR is strongly positive (above +20%), so no TSR-based AGAINST votes are warranted. No director is overboarded, all met the 75% attendance threshold, all independent directors serve only on independent committees, and no familial relationships with management were disclosed. The slate is recommended FOR in full.
Say on Pay
✓ FORCEO
Sheri L. Dodd
Total Comp
$3,466,916
Prior Support
98%%
CEO Sheri Dodd received total compensation of $3,466,916 in 2025, which is a reasonable level for a CEO at a $605 million medical device company in her first full year in the role. The pay structure is well-designed: roughly 58% of total compensation comes from variable, performance-linked sources (equity awards and cash bonus), well above the 50% threshold required by policy. Performance stock awards use multi-year revenue and Adjusted EBITDA metrics with clear numerical targets, and the annual cash bonus paid out at 115% of target based on actual results that exceeded goals — reflecting genuine pay-for-performance alignment. The prior year say-on-pay vote received approximately 98% support, and the company's strong stock performance over three years (+67.0% vs. +4.5% for the IHI — iShares US Medical Devices ETF) further supports the conclusion that incentive pay was earned. The company also maintains both a required clawback policy and a supplemental misconduct clawback policy, adding meaningful governance protection.
Auditor Ratification
✓ FORAuditor
Grant Thornton LLP
Tenure
11 yrs
Audit Fees
$704,600
Non-Audit Fees
$0
Grant Thornton has audited Tactile Medical since 2015 (approximately 11 years), well below the 25-year tenure threshold that would raise concerns. The company paid $704,600 in audit fees in 2025 and zero in non-audit fees, so the non-audit fee ratio is 0% — far below the 50% threshold that would trigger a concern about auditor independence. No material financial restatements were disclosed. Grant Thornton is a large national firm appropriate for a company of this size and complexity.
Overall Assessment
The 2026 Tactile Medical annual meeting presents a straightforward ballot with no significant governance concerns. All four proposals — the full nine-director slate, auditor ratification of Grant Thornton, advisory approval of executive pay, and a charter amendment to ease director removal — merit support based on strong stock performance relative to the IHI — iShares US Medical Devices ETF, a clean auditor fee profile with zero non-audit fees, a well-structured pay program with genuine performance linkage, and a shareholder-friendly charter improvement.